Phathom (PHAT) Q3 2026 Earnings Call Transcript
Phathom (PHAT) Q3 2026 Earnings Call Transcript（摘要待生成）
Jefferies cuts PHAT target to $16 from $20, keeps Buy
On October 14, 2026, Jefferies analyst Glen Santangelo lowered the target to $16 from $20 and maintained Buy. Jefferies expected Q3 results to align with consensus and cited 2027 guidance as a source of clarity; it noted a competitor PCAB PDUFA decision expected in January 2027. PHAT rose 5.71% that day, closing at $7.40.
PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity
PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity Stocktwits
Phathom Pharmaceuticals Addresses Litigation Filed by BDR Pharmaceuticals Against FDA
Phathom Pharmaceuticals announced that BDR Pharmaceuticals has filed a lawsuit against the FDA challenging the agency's refusal to accept an ANDA referencing Phathom's VOQUEZNA, specifically contesting the extension of Phathom's NCE exclusivity.
PHAT shares fell 18.33% on October 23 amid no identified company-specific catalyst
On October 23, 2026, PHAT closed at $5.725, down 18.33% on 4.34 million shares, after trading as low as $5.01, a new 52-week low per the page. The source does not identify a company-specific cause; no peer comparison or explanation was reported.
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 29, 2026
Phathom Pharmaceuticals has scheduled a live webcast for October 29, 2026, to discuss its third quarter 2026 financial results and provide a business update.